title: Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation.
abstract: BACKGROUND
  Many patients receiving amiodarone therapy are male. The long-term risk for amiodarone-induced thyroid dysfunction in these patients has not been systematically and prospectively investigated. The purpose of this study was to determine the extent of amiodarone-induced thyroid dysfunction in a large male cohort.
  
  
  METHODS
  This is a substudy of a prospective randomized controlled trial (SAFE-Trial) in which amiodarone, sotalol, and placebo for persistent atrial fibrillation were evaluated. For the purpose of this substudy, sotalol and placebo groups were combined into a control group. Serial thyroid function tests were performed over 1-4.5 years. Of the 665 patients enrolled in the SAFE-Trial, 612 patients were included in this sub-study.
  
  
  RESULTS
  Subclinical hypothyroidism, thyroid-stimulating hormone (TSH) level 4.5-10 mU/L, was seen among 25.8% of the amiodarone-treated patients and only 6.6% of controls (P <.0001). Overt hypothyroidism, TSH level >10 mU/L, was seen among 5.0% of the amiodarone-treated patients, and only 0.3% of controls (P <.001). By 6 months, 93.8% of the patients who developed TSH elevations above 10 mU/L on amiodarone had been detected. There was a trend toward a greater proportion of hyperthyroidism, defined as a TSH <0.35 mU/L, in the amiodarone group compared with the control group (5.3% vs 2.4%, P=.07).
  
  
  CONCLUSIONS
  Hypothyroidism developed in 30.8% of older males treated with amiodarone and in only 6.9% of the controls. Hypothyroidism presented at an early stage of therapy. Hyperthyroidism occurred in 5.3% of amiodarone treated patients, and was a subclinical entity in all but 1 case.
authors: West Los Angeles Veterans Affairs Medical Center, Los Angeles, Calif, USA. batcherb@gmail.com
authors: Elizabeth L
authors: EL
authors: Batcher
authors: X Charlene
authors: XC
authors: Tang
authors: Bramah N
authors: BN
authors: Singh
authors: Steven N
authors: SN
authors: Singh
authors: Domenic J
authors: DJ
authors: Reda
authors: Jerome M
authors: JM
authors: Hershman
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000139:chemically induced / Q000188:drug therapy; D007037:Hypothyroidism / Q000139:chemically induced / Q000188:drug therapy; D008297:Male; D016017:Odds Ratio; D010043:Outcome and Process Assessment, Health Care; D013015:Sotalol / Q000627:therapeutic use; D013959:Thyroid Diseases / Q000139:chemically induced*; D013974:Thyroxine / Q000627:therapeutic use
chemical_list: D000889:Anti-Arrhythmia Agents; D013015:Sotalol; D000638:Amiodarone; D013974:Thyroxine